Catalyst Pharmaceuticals, Inc: Kevin Kotler’s Broadfin Capital Disclosed Stake

February 14, 2018 - By Richard Conner

 Catalyst Pharmaceuticals, Inc: Kevin Kotler's Broadfin Capital Disclosed Stake

Investors sentiment decreased to 2 in 2017 Q3. Its down 0.22, from 2.22 in 2017Q2. It dropped, as 3 investors sold Catalyst Pharmaceuticals, Inc. shares while 15 reduced holdings. 17 funds opened positions while 19 raised stakes. 34.72 million shares or 4.30% more from 33.29 million shares in 2017Q2 were reported.

Legal And General Group Plc stated it has 10,602 shares. Moreover, Virtu Financial Limited Liability has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 30,372 shares. Vantage Inv Ltd Llc accumulated 3,000 shares. Principal Gp reported 11,220 shares. Consonance Capital Mngmt Limited Partnership has invested 0.1% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Royal Bancorp Of Canada accumulated 171,487 shares or 0% of the stock. State Street accumulated 0% or 944,295 shares. Goldman Sachs Gru Incorporated owns 45,568 shares. Aqr Capital Mgmt Ltd Limited Liability Company has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Manufacturers Life Insur Communications The has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Citadel Limited Liability Corp reported 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). California State Teachers Retirement invested in 0% or 117,600 shares. Venbio Select Advisor Llc has 4.64 million shares. Alliancebernstein L P invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Weiss Multi reported 30,000 shares.

The New Kevin Kotler’s Broadfin Capital Holding in Catalyst Pharmaceuticals, Inc

Broadfin Capital reported SC 13G/A form with the SEC for Catalyst Pharmaceuticals, Inc. Access it here: 000091957418001185. As reported by Kevin Kotler’s Broadfin Capital, the filler owns 6.93% or 7,097,300 shares of the Health Care–company.

Catalyst Pharmaceuticals, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Kevin Kotler’s Broadfin Capital’s positive view for Catalyst Pharmaceuticals, Inc. For a hedge fund managing $1.26 billion in assets and having 10+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Kevin Kotler’s Broadfin Capital’s portfolio is in the sector.

Catalyst Pharmaceuticals, Inc Institutional Sentiment

Filings show 89 investors own Catalyst Pharmaceuticals, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 5659252. 49229682 were owned by these investors. 15 funds opened new Catalyst Pharmaceuticals, Inc stakes, 28 increased positions. There were 11 that closed positions and 27 reduced them.

Arthur B Cohen And Joseph Healey Healthcor Management Lp is an investor bullish on Catalyst Pharmaceuticals, Inc, owning 385500 shares as of Q3 2015 for 0.07% of its portfolio. Julian Baker And Felix Baker Baker Bros Advisors Lp owns 7335692 shares or 0.20% of its portfolio. NY Tanaka Capital Management Inc have 0.85% of its portfolio for 111693 shares. Further, Broadfin Capital Llc reported stake worth 0.70% of its portfolio. The NY Consonance Capital Management Lp owns 5802885 shares. Catalyst Pharmaceuticals, Inc is 2.45% of its portfolio.

Business Profile

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.

SEC Form 13G.

Kevin Kotler’s Broadfin Capital website.

Analysts await Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report earnings on March, 21. They expect $-0.06 EPS, down 20.00 % or $0.01 from last year’s $-0.05 per share. After $-0.05 actual EPS reported by Catalyst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

The stock increased 1.19% or $0.04 during the last trading session, reaching $3.41. About 292,218 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 267.48% since February 14, 2017 and is uptrending. It has outperformed by 250.78% the S&P500.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $349.44 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette's disorder; and CPP-109 to treat Tourette's disorder.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ratings Coverage

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals has $8.0 highest and $4 lowest target. $5.75’s average target is 68.62% above currents $3.41 stock price. Catalyst Pharmaceuticals had 13 analyst reports since April 26, 2016 according to SRatingsIntel. As per Tuesday, April 26, the company rating was downgraded by Piper Jaffray. Roth Capital maintained the stock with “Buy” rating in Wednesday, August 30 report. H.C. Wainwright maintained the stock with “Buy” rating in Friday, August 11 report. Piper Jaffray maintained the stock with “Buy” rating in Monday, August 7 report. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Friday, November 10 report. PiperJaffray upgraded the stock to “Overweight” rating in Wednesday, October 5 report. The company was maintained on Tuesday, October 31 by SunTrust. SunTrust maintained the shares of CPRX in report on Monday, November 27 with “Buy” rating. The stock has “Buy” rating by Roth Capital on Thursday, August 10. The rating was maintained by SunTrust with “Buy” on Friday, September 1.

Another recent and important Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news was published by which published an article titled: “Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for …” on February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.